Fed Sinks Markets
Health Care: Drugs
Opexa Therapeutics Inc. (OPXA: NASDAQ)
$1.51 0.02 | 1.34%
06/19/13 - 03:59 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling, General, and Administrative Expenses | 2.51M | 2.41M | 2.22M | 2.02M |
| Research & Development | 6.32M | 3.34M | 2.58M | 2.11M |
| Operating Income before D & A (EBITDA) | -8.83M | -5.75M | -4.80M | -4.13M |
| Depreciation & Amortization | 466.35K | 210.25K | 591.71K | 389.95K |
| Interest Income | 280.00 | 932.00 | 1.66K | 1.76K |
| Other Income - Net | 549.88K | -9.69K | -459.00 | 3.19M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -8.74M | -5.97M | -5.39M | -1.33M |
| Interest Expense | 350.30K | 3.14K | 500.65K | 278.13K |
| Pre-Tax Income | -9.09M | -5.97M | -5.89M | -1.61M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -8.93M | -5.97M | -5.47M | -1.43M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -8.93M | -5.97M | -5.47M | -1.43M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -8.93M | -5.97M | -5.47M | -1.43M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-8.93M | -5.97M | -5.47M | -1.43M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -8.93M | -5.97M | -5.47M | -1.43M |
| Basic EPS from Continuing Ops. | -1.54 | -1.04 | -1.28 | -0.44 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -1.54 | -1.04 | -1.28 | -0.44 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -1.54 | -1.04 | -1.28 | -0.44 |
| Basic Normalized Net Income/Share | -1.54 | -1.04 | -1.28 | -0.44 |
| EPS fr Continuing Ops. | -1.54 | -1.04 | -1.28 | -0.44 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -1.54 | -1.04 | -1.28 | -0.44 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -1.54 | -1.04 | -1.28 | -0.44 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-1.54 | -1.04 | -1.28 | -0.44 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with OPXA
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- Userneed cash
- UserYaYa
- UserHealthCare Dares
- UserBENITRANS CX
Latest OPXA Headlines from TheStreet
- 5 Stocks Poised for Breakouts 06.07.13 | 02:06 pm
- 4 Health Care Stocks Under $10 to Watch 05.31.13 | 02:05 pm
- 4 Biotech Stocks Under $5 to Watch 03.15.13 | 07:03 am
- Stocks Rebound Sharply; S&P 500, Nasdaq Rise Over 1% 02.05.13 | 04:02 pm
- Investors Overreact to Opexa Finding Scant Interest for Failed Multiple Sclerosis Drug 02.05.13 | 10:02 am
- 5 Stocks Poised for Breakouts 10.12.12 | 01:10 pm
- Lessons From Biotech's Best Third Quarter Stocks 10.02.12 | 09:10 am
- Biotech Stock Mailbag: Best Stocks to Watch in '11 01.07.11 | 07:01 am
- Opexa Therapeutics Reports Third Quarter 2010 Financial Results 11.09.10 | 08:11 am
- Otix Global, Entropic: Volume Movers 09.13.10 | 02:09 pm
Press Releases for OPXA
- Opexa Therapeutics To Present At The 6th Annual European Life Science CEO Forum - Business Wire 03.04.13 | 08:03 am
- Opexa Therapeutics, Inc. Announces Pricing Of Common Stock And Warrant Offering - Business Wire 02.07.13 | 09:02 am
- Opexa Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference - Business Wire 02.07.13 | 08:02 am
- Merck Serono And Opexa Therapeutics Enter Into Option And License Agreement For Development Of Tcelna™ (imilecleucel-T) For Treatment Of Multiple Sclerosis - Business Wire 02.05.13 | 07:02 am
- Opexa Therapeutics Closes Private Note Offering - Business Wire 01.23.13 | 05:01 pm
- Opexa Therapeutics Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement - Business Wire 01.15.13 | 08:01 am
- Opexa Therapeutics Announces Reverse Stock Split - Business Wire 12.14.12 | 04:12 pm
- Opexa Therapeutics Reports Third Quarter 2012 Financial Results And Provides Corporate Update - Business Wire 11.14.12 | 08:11 am
- Opexa Receives Clinical Trial Approval From Health Canada For Novel T-Cell Therapy - Business Wire 11.13.12 | 08:11 am
- Opexa Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference - Business Wire 11.12.12 | 03:11 pm
Partner Headlines for OPXA
- Benzinga's Microcap Movers for Friday July 13, 2012 - Benzinga 07.14.12 | 04:07 pm
- A Busy Week for Multiple Sclerosis News - Seeking Alpha 09.26.10 | 08:09 am
